<DOC>
	<DOCNO>NCT00551785</DOCNO>
	<brief_summary>The primary objective study assess risk testosterone transdermal patch use representative study population . The primary clinical outcome interest breast cancer .</brief_summary>
	<brief_title>Surveillance Study Women Taking Intrinsa®</brief_title>
	<detailed_description>This prospective , control , non-interventional long-term cohort study woman prescribe estrogen therapy estrogen therapy combination Intrinsa® . Intrinsa® transdermal patch delivers 300 mcg testosterone daily skin abdomen , provide woman testosterone level within physiological range premenopausal woman . It indicate treatment hypoactive sexual desire disorder ( HSDD ) woman bilateral oophorectomy hysterectomy receive concomitant estrogen therapy . A non-interference approach use provide standardize , comprehensive , reliable information treatment routine medical condition . The two main objective study : - estimate incidence breast cancer , gynecological cancer , myocardial infarction , cardiovascular outcome rare serious adverse outcome among Intrinsa® user actual clinical practice , - compare incidence incidence find comparison group woman bilateral oophorectomy hysterectomy use estrogen therapy . The primary variable statistical analysis breast cancer hazard ratio Intrinsa® user comparison user estrogen therapy . The secondary objective study : - analyze Intrinsa® utilization pattern study population representative user novel treatment - characterize baseline risk Intrinsa® user breast cancer cardiovascular diseases - investigate reversibility specific androgenic outcome stop treatment . The two study cohort consist new user Intrinsa® combination estrogen therapy estrogen therapy without simultaneous use Intrinsa® , respectively . After study entry cohort member follow period five eight year rare serious safety outcome . Regular , active contact cohort member ZEG study team ( =active surveillance ) provide necessary information health-related event change health status . All cohort member contact 6 12 month study entry , every 12 month . Approximately 5.400 subject per cohort recruit participate physician order provide 50.000 women-years ( WY ) observation , assume withdrawal rate 10 % per year . Enrollment procedure interfere prescribe behavior physician individual need participate woman . The study conduct Italy , France , Spain , UK Germany . It could extend country base international registration launch status Intrinsa® . The study divide two phase : clinic phase , include initial consultation baseline participate physician , follow-up phase , include two follow-up contact within first year , annual follow-up contact eight year post-baseline . The study participant woman new prescription Intrinsa® combination estrogen therapy estrogen therapy respectively willing participate cohort study . There specific medical inclusion exclusion criterion guidance provide local product label . However , woman cooperative may exclude study participation . Also woman language barrier eligible study inclusion . This study maintain scientific independence govern independent Advisory Council . The Center Epidemiology Health Research Berlin , Germany research team accountable Advisory Council ( AC ) scientific matter . The member AC wil international expert relevant scientific field ( e. g. epidemiology , gynecology cardiology ) . Information identity patient treat physician keep separated clinical information throughout study . All relevant national data protection law follow .</detailed_description>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<criteria>All woman bilateral oophorectomy hysterectomy receive new prescription study medication prescribe period six month less study entry Women baseline use Intrinsa® new estrogen therapy six month Women consent participate study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hypoactive Sexual Desire Disorder</keyword>
	<keyword>Menopause</keyword>
	<keyword>Androgen</keyword>
</DOC>